Netherlands

Dutch Minister of Care announces mandatory “base stocks” to prevent medicine shortages

Sophie van Asten

On 4 November 2019, the Dutch Minister of Care wrote a letter to the House of Representatives, proposing a solution for medicine shortages. In order to prevent shortages, additional stocks of medicines should be built up by obliging medicine manufacturers and wholesalers to build up mandatory buffers (“base stocks”) of five months’ duration, starting in Read More

Netherlands: ACM publishes evaluation of collective procurement of prescription medicines guidelines

Iradj Nazaryar

In early November 2019, the Dutch Authority for Consumers & Markets (ACM) published an evaluation of its guidelines on collective procurement of prescription medicines (2016). The guidelines provide an overview of the various options healthcare insurers and hospitals have for the collective procurement of medicine without infringing competition law, in order to create a stronger Read More

Netherlands: Debate between Dutch Minister of Care and pharmaceutical companies

Lars Braams

On 27 August 2019, the Dutch Minister of Care wrote an open letter in one of the main Dutch newspapers (De Volkskrant), addressed to pharmaceutical companies. In the letter he requested price transparency. He stated that when an explanation for a price increase is proposed by a pharmaceutical company (for example, high development costs or Read More

Netherlands: Hospitals request three-year suspension of Dutch Competition Act

Hannah Smit

The Dutch Association of Hospitals (NVZ) has published a press release announcing that it has appealed for a three-year temporary suspension of the Dutch Competition Act in the healthcare sector, as various healthcare institutions have entered into arrangements to save on costs that may be in violation of the Act. For example, the institutions have Read More

Excessive pricing practices in the pharmaceutical sector – NCAs’ scrutiny continues

Nele De Backer

Last week, the Belgian and Italian consumer associations Test Aankoop/Test Achats and Altroconsumo filed complaints with their respective national competition authorities, alleging that the pharmaceutical group Biogen is abusing its dominant position by charging excessively high prices for the medicine Spinraza, which it has the exclusive right to market as an orphan drug until 2029. Read More